Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Paul-Ehrlich-Institut Permits the Import of Vimkunya with French Labelling

Vimkunya is a travel vaccine that protects adults and adolescents 12 years of age and older from diseases caused by the chikungunya virus. The marketing authorisation holder Bavarian Nordic A/S has reported a shortage of the vaccine that is expected to last from 22 November to 29 December 2025. In order to meet the expected demand during this period, the Paul-Ehrlich-Institut (PEI) has permitted Bavarian Nordic to place packs of Vimkunya on the market in Germany from 1 December to 28 December 2025 pursuant to section 10 (1a) and section 11 (1c) of the Medicinal Products Act (Arzneimittelgesetz, AMG). This product is pharmaceutically identical to the product with German labelling and differs only in the packaging.

Details

  • The commercial name of this French-labelled product is also Vimkunya (see photos below).
  • The text on the syringe label, in the package leaflet, and on the folding box is in French.
  • The vaccine, which is labelled in French, is supplied with a package leaflet in German, which is taped to the French packaging.
  • The package leaflet and the summary of product characteristics are available for download on this page.
  • Pharmaceutical form: pre-filled syringe without needle
  • PZN: 20346657
  • Batch number: FDP00745
  • Expiration date: 29 February 2028

Image / Video 2 / 3

Medicine Vimkunya Back with French labelling. Medicine Vimkunya Back with French labelling. Source: Bavarian Nordic

Pagination

back: …

How should the vaccine be used?

The instructions listed in the package leaflet must be followed.

Background

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, is the higher federal authority responsible for the quality, safety and efficacy of vaccines in Germany and for the official batch release of vaccines and biomedicines. It also advocates for the availability of these medicines.

An overview of current supply shortages of human vaccines in Germany can be found on the page linked below.

Our email newsletter "Safety and Availability – Information on Drug Safety, Handling Information on Supply Bottlenecks of Human Vaccines" provides regular information about current availability and supply shortages.

Updated: 28.11.2025